Legal action from Bracco Diagnostics, Inc. regarding patent infringement

Montreal, QC, April 4, 2018 – Jubilant DraxImage Inc. (“DraxImage”), recently learned of legal challenges filed by Bracco Diagnostics, Inc. (“Bracco“) including a complaint filed with the U.S. International Trade Commission (ITC) regarding alleged patent infringement related to the Jubilant DraxImage product, RUBY-FILL®.

We have carefully reviewed the allegations made by Bracco and intend to vigorously defend our legal positions. We are very confident that ultimately Jubilant DraxImage will be successful in this litigation and do not expect the litigation to affect the continuing availability of RUBY-FILL® products in the United States or elsewhere.

The RUBY-FILL® Generator and the RUBY Elution System provide the latest and most advanced technology in PET Rubidium-82 myocardial imaging, which is focused on the original charter of an improved safety profile through improved technology. The RUBY Elution System (RbES) and the proprietary RUBY consumable accessories are used only with the RUBY-FILL® Rubidium-82 Generator for Positron Emission Tomography (PET) imaging of the myocardium, manufactured only by Jubilant DraxImage, Inc. The RUBY-FILL Generator and the RUBY Elution system are currently available throughout the US today, and are a key part of Jubilant DraxImage’s greater commitment to investing in the growth and the continued advancements of nuclear medicine globally and especially in the global cardiology market.

The RUBY-FILL technology is very advanced and is currently not available through any other source in any market. It offers significant advancements in efficiency, dose accuracy, infusion protocols, and many automated safety and quality control features, to assure safe and consistent doses for the benefit of every patient.

Jubilant DraxImage remains committed to providing this advanced technology to our US customers as well as the global imaging industry, now and in the future, and will continue to operate in the normal course of business providing this product moving forward. For more information on RUBY-FILL and the RUBY Elution System technology features and benefits, please visit the website at or

 For inquiries related to this action, please contact:

Ms. Sarah Marquis, Director Legal Affairs
Jubilant DraxImage, Inc.

For product inquiries, please contact:

Mr. James A. Kaufman, VP Marketing
Jubilant DraxImage, Inc.


INDICATION: RUBY-FILL is a closed system used to produce rubidium (Rb-82) chloride injection for intravenous use. Rubidium (Rb-82) chloride injection is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

 Important Safety Information

Please visit for full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088

3 Responses to “Important Customer Communication”

  1. Robert deKemp

    I am disappointed that Bracco has taken this action to attempt to prevent patient access to the JDI Ruby-Fill and Elution System. This technology was developed originally by my research team at the uOttawa Heart Institute and licensed to JDI (then DraxImage) in 2007. JDI invested heavily over the next 10 years to bring this new technology to market, with FDA approval obtained in 2017, whereas Bracco is selling a competing product that has not been updated significantly in over 30 years.

  2. William Lepeak

    If you can not beat them then hire a lawyer and sue them. A sure sign of a of a weak market for 20 year old technology.
    Best Wishes

    • donna schork

      Dear Mr. Lepeak,

      Thank you for your email and your words of encouragement. Rest assured, we have carefully reviewed the allegations and will vigorously defend our legal position. We are very confident that ultimately we will be successful in this litigation and do not expect it to affect the continuing availability our advanced technology.


Leave a Reply

Share this news!